PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets

TOKYO, Japan, 14 April 2025 — PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc., effective April 1, 2025.

This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab’s proprietary peptide mimetic technology for controlling protein-protein interactions with Elix’s cutting-edge AI drug discovery platform.

For more details, please click here